Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

AF38469 is an inhibitor of sortilin, also known as the neurotensin-3 receptor (NTS3; IC50 = 330 nM).1 It is selective for sortilin over neurotensin-1 (NTS1), δ-opioid, angiotensin II type 1 (AT1), endothelin A (ETA), and ETB receptors, GPR40, PPARδ, and matrix metalloproteinase-12 (MMP-12), and the prostaglandin E2 (PGE2) receptor subtype EP1. AF38469 (400 nM) inhibits the epithelial-to-mesenchymal transition (EMT) in, and reduces migration and invasion of, U87 and A172 glioblastoma cells.2 It also reduces tumor growth in a glioblastoma multiforme mouse xenograft model when administered at a dose of 0.01 g/kg per day.
WARNING This product is not for human or veterinary use.
1. The identification of AF38469: An orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin. Bioorg. Med. Chem. Lett. 24(1), 177-180 (2014).
2. Sortilin promotes glioblastoma invasion and mesenchymal transition through GSK-